Trial Profile
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms ACTT-2; ACTT-II
Most Recent Events
- 29 Nov 2022 Results post hoc of analysis compared recovery and mortality between these comparable sequential cohorts of patients who received remdesivir plus SOC, adjusting for baseline characteristics with propensity score weighting published in the Annals of Internal Medicine
- 11 May 2022 According to a Eli Lilly and Company media release, based on the ACTT-2 and COV-BARRIER studies, the USA Food and Drug Administration (FDA) has approved OLUMIANT (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.
- 22 Nov 2021 Results evaluating cost-effectiveness of BARI-REM versus REM using data from the ACTT-2, published in the Advances in Therapy